Campylobacter Infections
9
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
LMN-101 in a Campylobacter Human Challenge Model
Recurrent Campylobacter Bacteraemia in Immunocompromised Patients
Campylobacter Spp. Bone and Joint Infection: a Retrospective Cohort Study
Protein Plus: Improving Infant Growth Through Diet and Enteric Health
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota
Retrospective Study of Bone Infection Due to Campylobacter Spp
Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection
Campylobacter Jejuni Challenge Model Development: Dose Ranging Study